Since the identification of MECP2 as the causative gene in the majority of Rett Syndrome (RTT) cases, transgenic mouse models have played a critical role in our understanding of this disease. The use of additional mammalian RTT models offers the promise of further elucidating critical early mechanisms of disease as well as providing new avenues for translational studies. We have identified significant abnormalities in growth as well as motor and behavioural function in a novel zincfinger nuclease model of RTT utilizing both male and female rats throughout development. Male rats lacking MeCP2 (Mecp2 ZFN/y ) were noticeably symptomatic as early as postnatal day 21, with most dying by postnatal day 55, while females lacking one copy of Mecp2 (Mecp2 ZFN/þ ) displayed a more protracted disease course. Brain weights of Mecp2 ZFN/y and Mecp2
Introduction
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder affecting approximately 1 in 10 000 girls annually (1) that is caused by mutations in the gene encoding the transcriptional regulator MeCP2 in over 95% of typical cases (2) (3) (4) (5) . The syndrome is marked by seemingly normal development until 6-18 months of age, at which point language, motor, social and cognitive skills regress, cephalic growth decelerates, and hand stereotypies and breathing abnormalities appear (5) (6) (7) (8) . Although emerging longitudinal data suggest that females with RTT may live well into their fifties (9) , the disease nonetheless has devastating impacts on quality of life.
Historically, RTT has been studied primarily through the use of genetically manipulated mouse models with alterations in the Mecp2 gene (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , all of which display a range of abnormal neurologic phenotypes. Overall, these models have been relatively successful in recapitulating many of the features observed in the clinical progression of RTT (for an extensive review of existing RTT mouse models, see references (23) (24) (25) (26) . Although many studies thoroughly examined phenotypes in overtly "symptomatic" male and less frequently female animals, few have fully characterized these models beginning early in development. Given that RTT is a pervasive developmental disorder presenting with an initial period of "normality" followed by severe regression and subsequent pseudostationary and deterioration phases, it is important to remain cognizant of the pathophysiologic changes that may occur in any model throughout each stage of development. This is especially critical when considering the potential for a targeted therapeutic window early in disease progression.
Although mice have long been the preferred species in the modelling of genetic disorders, relatively recent advances in the ability to manipulate the rat genome offer unique opportunities, especially in the study of central nervous system (CNS) diseases like RTT. Relative to the mouse, the increased size of the rat, and subsequently all of its anatomical structures, offers obvious advantages in a surgical setting, but confers additional benefits when considering the importance of structure size and spatial relationship in both region-specific and age-dependent studies of the CNS. Electrophysiological studies and direct drug delivery experiments, for example, are considerably easier when dealing with large rat structures, an effect that is magnified if studies are performed at very early developmental stages. It is also well established that, compared to mice, rats demonstrate a wider variety of more complex cognitive and social behaviours for which testing paradigms are available and validated (27) (28) (29) (30) (31) (32) (33) (34) (35) . All of these factors make the use of a rat model an appropriate choice for the study of a neurodevelopmental disorder such as RTT, in which deficits of higher cognitive functioning and social interaction predominate, and examination at early developmental time points may be critically relevant to therapeutic potential. Aside from these specific advantages, the addition of a rat model to the collection of resources currently available in the study of RTT will provide a platform for validating and comparing behavioural phenotypes in different species with different genetic backgrounds, thus making possible a more complete understanding of complex disease mechanisms which will facilitate translatable pharmaceutical development.
With these considerations in mind, we sought to establish the utility of a novel zinc-finger nuclease rat model of RTT, generated by Sage laboratories, by characterizing its motor and behavioural phenotypes that recapitulate the fundamental features observed in existing RTT mouse models as well as human RTT patients. This model contains a 71 base pair deletion in exon 4 of the Mecp2 gene, resulting in the absence of MeCP2 protein. As one of the first characterizations of the motor and behavioural phenotypes in this model, we felt it important to follow both male and female rats through the entirety of their development. We herein report that brain weight is reduced in this RTT rat model by postnatal day (PND) 14, both motor and behavioural deficits are clearly observed as early as the fourth postnatal week, and these deficits continue throughout development. 
Results

Mecp2
ZFN/y and Mecp2 ZFN/þ rats display diminished overall wellness and decreased survival A symptom score was generated for the animals used in this study by weekly monitoring for general wellness, and the presence and severity or absence of specific characteristics. Possible symptom scores ranged from 0 to 9 ( 
. Data are presented as mean 6 SE, with asterisks representing significant genotype differences (**P < 0.01). 
ZFN/þ females are significantly heavier than WTs beginning at postnatal day 60 and continuing through 18 months 
. Data are presented as mean 6 SE, with asterisks representing significant genotype differences (*P < 0.05, **P < 0.01, ***P < 0.00 1 (Fig. 3A) . Mecp2 ZFN/þ females displayed a more gradual increase in symptom score from PND 21-28 through 9 months of age, with the average score being between 3 and 4 for 9-month-old Mecp2 ZFN/þ rats (Fig. 3B) . WT male and female symptom scores above 0 were typically due to a mild developmental decrease in activity level, which is reflected in Figure 4A -G, or by fur loss around the face and dorsal body, which followed a pattern of cagemate-initiated barbering that has previously been reported in rodents (45) . Hindlimb clasping (Fig. 3C) Fig. 4A-C) . A representative activity tracing from one trial in late symptomatic animals is shown in Figure 4D . Unlike open field testing, which assesses the general activity level of a freely moving animal, rotor rod tests motor coordination while providing motivation by exploiting a natural fear of falling off of the rotating rod. We observed a significant decrease in latency to fall in Mecp2 ZFN/y rats relative to WT littermates at both early (PND 21-28) and late (PND 40þ) developmental time points (Fig. 5A ). Mecp2 ZFN/þ females also demonstrated a decreased latency to fall at 9 months of age compared to WT littermate controls (Fig. 5B ). Testing of females older than 9 months of age was not assessed due to the frequency of obesity in the Mecp2 ZFN/þ population, which made placement on the rotating rod not possible. Given the abnormal gait we observed in male and female animals, we additionally pursued more complex gait analysis via 
demonstrates that half of Mecp2 ZFN/y males have died by PND $55 (WT n ¼ 11
. Data are presented as mean 6 SE, with asterisks representing significant differences (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (E-G) Mecp2 ZFN/þ females display a significantly decreased distance travelled (E) and average velocity (F) at 12 months of age when compared to WT females, as well as (G) decreased time spent in a highly mobile state at 6 and 12 months of age (PND 21-28 WT n ¼ 11 Mecp2
. Data are presented as mean 6 SE, with asterisks representing significant genotype differences (*P < 0.05, **P < 0.01, ***P < 0.001). 7A ) and number of steps increased at both 6 and 9 months of age (Fig. 7B) . Usage of 3-paw support during movement was decreased in Mecp2 ZFN/þ rats at one week post-weaning as well as 12 and 15 months of age (Fig. 7C) . The base of support, or width of stance, between hind paws was found to be increased in Mecp2 ZFN/þ rats beginning at 6 months of age and continuing through 15 months of age (Fig. 7D) (Fig. 8F) , minute ventilation (5758 6 425.0 ml/min/kg WT vs. 5368 6 505.4 ml/min/kg Mecp2 ZFN/y ) (Fig. 8G) , a relatively stable respiratory cycle (irregularity score ¼ 5.0 6 0.6 WT vs. 5.1 6 0.6 Mecp2 ZFN/y ) (Fig. 8H) , and a similar number of spontaneous apneas (Fig. 8I ), but of a shorter duration compared to controls (2.5 6 0.1 s WT; 2.1 6 0.1 s Mecp2 ZFN/y ) ( Fig. 8J and B (Fig. 8J) , but with otherwise normal outcome measures (Fig. 8D-I (Fig. 9B) . All other outcome measures were normal in Mecp2 ZFN/þ females ( Fig. 9C-H ).
Regardless of age or gender, apneic events were typically preceded by a sigh-like augmented breath in both WT and MeCP2-deficient animals (Fig. 8B) ; however, unlike WT animals, Mecp2 ZFN/y rats showed little expiratory component associated with this augmented breathe, perhaps suggestive of breath-hold like behaviour. It is worth noting anecdotally that juvenile and adult WT rats showed spontaneous apneic events in a stochastic manner, whereas age matched Mecp2 ZFN/y rats tended to have multiple apneas consecutively (Fig. 8B ). For example, only 0% and 2.7% of apneas observed in juvenile and adult WT rats occurred within 5 sec of another apnea, whereas 15% of all apneas observed in age matched Mecp2 ZFN/y rats occurred within 5 sec of another apnea. This tendency for consecutive apneas is consistent with an unstable pattern of breathing.
Discussion
This rat study represents the first RTT developmental and behavioural evaluation of its kind outside of traditional murine models of the disease. Our data indicate that male RTT rats demonstrate a complete absence of MeCP2 protein and an early onset of rapidly progressive disease, with $50% dying by PND 55. No Mecp2 ZFN/y rat in our study survived past PND 72.
Mecp2
ZFN/þ rats show an approximate 50% reduction in MeCP2 protein and a more protracted, variable, and less severe disease progression than that of affected males. Our data indicate that 
ZFN/y n ¼ 10; PND 50þ WT n ¼ 12 Mecp2 ZFN/y n ¼ 14). Data are presented as mean 6 SE, with asterisks representing significant differences (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
the current rat model displays a variety of phenotypic characteristics reminiscent of classical RTT, which positions it as a valuable mammalian model for future studies. A relative comparison of this model to other murine RTT models is provided in Table 2 .
General RTT phenotype
In females with RTT, disease overtly presents between 6-18 months of age, and symptom progression occurs over a period of years. In XY males, however, mutations in MECP2 result in fatal neonatal encephalopathy due to the x-linked nature of the disease, or, rarely, a more classical RTT presentation (47) (48) (49) .
Paralleling findings in humans, Mecp2 ZFN/y rats became symptomatic within weeks of birth and died early, all findings that are corroborated by earlier reports in various mouse models (10) (11) (12) (20) (21) (22) 37, 50, 51) .
While male animal models have long provided utility in the study of RTT due to their advanced disease time course as well as a relative lack of phenotypic variability, the additional 
are presented as mean 6 SE, with asterisks representing significant differences (*P < 0.05, **P < 0.01, ***P < 0.001).
examination of female animal models is critical for both a comprehensive understanding of disease phenotype, which depends heavily on random X-chromosome inactivation in female patients, and a prediction of therapeutic potential (52, 53) . Similar to reports in RTT mouse models, we found that Mecp2 ZFN/þ rats became symptomatic on a more variable and lengthened time course than males, with most displaying overt progressive symptoms between 6 and 9 months of age.
Body weight and brain size in RTT
Females with RTT often display abnormalities in growth, including body weight regulation, leading to the incidence of both overweight and underweight individuals within the disease population (54) (55) (56) . Additionally, it has long been known that RTT females display microcephaly on a gross anatomic scale, with brain volume generally being reduced by 25% (57-59).
Mouse models of RTT have demonstrated a wide variety of genotype-specific weight changes, with strain background being considered a major determinant of this feature. Similar to two previous reports (14,15), we found that body weight was the same between Mecp2 ZFN/y rats and WTs at all time points. In contrast, we report a significant increase in Mecp2 ZFN/þ body weight beginning at 2-3 months of age and continuing through development. Several previous mouse studies also report weight gain in heterozygous females (11,13,42,44). 
Mecp2
ZFN/y n ¼ 7). Consistent with reduced respiratory frequency, juvenile Mecp2 ZFN/y rats also showed an increase in Ti (D) and Te (E). Data are represented as mean 6 SEM, with asterisks representing significant differences (*P < 0.05, **P < 0.01, ***P < 0.001). _ designates sigh-like augmented breaths; # identifies apneic events.
We additionally found that Mecp2 ZFN/y wet brain weight was decreased by PND 14, preceding significant findings on other behavioural tests evaluated herein as well as previous reports of reduced brain volume and weight in PND21þ male mice (36, 40) . In affected female mice, small (4%) reductions in brain volume have been reported as early as PND 21 by magnetic resonance imaging (40), matching our report of sustained reduction in Mecp2 ZFN/þ brain weight beginning early in development. All of our findings coincide with early abnormalities in ultrasonic vocalization, postural reflex, and breathing patterns reported in several mouse studies (39, (60) (61) (62) (63) .
Motor dysfunction
Impairments in motor skills are prominent features in RTT, with the majority of patients either never gaining the ability to walk or losing this skill by adulthood (64) (65) (66) . Subtle alterations in general movements may be observable in infants within the first several months of life (67, 68) , and various abnormalities in muscle tone are often present both early and late in the disease course (64, 65, 69 with significance being reached periodically beginning at 6 months of age. This generalized lethargy and reduction in free ambulation has also been observed in male and female RTT mice relatively early in development (10, 22, 39, (70) (71) (72) (73) (74) .
When testing paradigms that incorporated motivational factors, such as fear of falling or an appealing dark box, were utilized such that motor coordination per se could be more specifically assessed, we observed that Mecp2
ZFN/y and
Mecp2
ZFN/þ rats performed more poorly overall than their WT counterparts. Similar to findings in previous studies (22) , Mecp2 ZFN/y rats demonstrated decreased latency to fall from a rotating rod as early as PND 21. Mecp2 ZFN/þ females demonstrated reduced latency to fall at 9 months of age; however, this difference did emerge after Mecp2 ZFN/þ rats became heavier than WTs, making it difficult to definitively determine a weight-independent effect. Previous studies have reported reductions in latency to fall in heterozygous females as early as PND 30 (22), while others have indicated that motor coordination deficits emerge between 5 weeks and 12 months of age (11, 13, 22, 37, 39, 42, 44, 73, 74) .
Gait assessment revealed alterations in the manner in which Mecp2
ZFN/y and Mecp2 ZFN/þ rats crossed a glass walkway; namely, 
2002.
*Preliminary grip strength and wire hang data not presented, addressed in discussion section.
they crossed more slowly, took a greater number of steps, and utilized different types of body support mechanisms to accomplish this goal. Trends toward altered features in Mecp2 ZFN/þ females generally reached significance at only some time points, which was not altogether surprising given the wide phenotypic variability commonly seen in female mouse models of RTT as well as female patients. Previous reports have demonstrated findings of decreased stride length and increased step frequency in male RTT mice as early as 3-4 weeks of age (37, 51, 71) , and gait ataxia as early as 1-4 months of age in heterozygous female mice (10, 11) . Interestingly, while the hindpaw width of stance was increased in Mecp2 ZFN/þ rats, a finding that has been previously reported in mice (51, 71) , forepaw width of stance and paw print areas were not correspondingly increased as may have been predicted from significant average body weight increases in Mecp2 ZFN/þ rats relative to WTs. The persistence of gait regularity (observed also in (71)) in the presence of these support type variations in both Mecp2 ZFN/y and Mecp2 ZFN/þ rats seems to indicate that profoundly symptomatic animals are capable of compensating to accomplish motivated ambulation.
Other physical and behavioural manifestations of disease
Malocclusion
The majority of Mecp2 ZFN/y rats ($80%), but only 5 Mecp2
females, demonstrated severe uneven tooth wear necessitating euthanasia during our study. Dental malocclusion has been observed in other RTT models (10, 12) . We assume that the low incidence of this feature in female rats was due to their possession of one functional Mecp2 copy; however, malocclusion was previously reported as a "common" occurrence in female mice (12) . Rodents' teeth grow continuously and require constant gnawing to maintain normal wear. Malocclusion may have indirectly resulted from a change in the animals' ability or desire to feed due to global MeCP2 absence, a feature that might parallel the gastrointestinal autonomic dysfunction and feeding difficulties observed in girls and boys with RTT (48, 75, 76) . Alternatively, malocclusion may directly result from MeCP2 absence in the peripheral tissues related to tooth development and growth; however, given that decelerated weight gain seemed to precede tooth lengthening and the time course of this feature's development varied significantly, it seems as though the former may be the more probable explanation. Regardless, the development of malocclusion will be critical to consider in any future study utilizing affected male rats. Stringent evaluation of weight gain/loss will be necessary to track potential nutritional deficits, and stratification of affected males into groups based on the development of malocclusion may yield interesting phenotypic findings.
Hind limb clasping
The development of hand stereotypies is a key diagnostic feature of classic RTT (5) (6) (7) (8) 77) . The presence of hindlimb clasping upon tail suspension in animal models of RTT has been suggested to recapitulate this principle finding, although this feature is observed in many rodent models of neurologic disease (78) (79) (80) (81) . In this study, the majority of Mecp2 ZFN/y and Mecp2 ZFN/þ rats displayed hindlimb clasping at some point during development, as has been previously reported in many mouse models of RTT.
Breathing irregularities
RTT patients often develop irregular breathing characterized by periods of hyperventilation interspersed with apnea or breath holds (82) . Mouse models of RTT typically report normal respiratory activity under control conditions (inactive, breathing room air) up to PND 20 (63,83) followed shortly thereafter by abnormalities in post-sigh breathing (63) , and later hyper-(84,85) or hypo-ventilation (62, 83, 86, 87) with increased tidal volume (86, 88) in conjunction with increased apneic frequency and duration (89) (90) (91) . These respiratory abnormalities are partly recapitulated in juvenile and adult Mecp2 ZFN/y rats, which demonstrate decreased respiratory frequency, as well as Mecp2 ZFN/þ rats, which show increased frequency. However, our evidence suggests that there are species-specific effects of MeCP2 deficiency on respiratory function. While reoccurring apneas are a characteristic breathing feature in RTT patients (82, 90, 91) and several mouse models of RTT (90, 91) , our data show that disruption of MeCP2 in rats does not lead to an overtly apneic phenotype. Furthermore, breathing irregularities in RTT mice typically develop after PND 30 and progressively worsen with age (62, 63, 83) . Our data in MeCP2 deficient rats suggest that respiratory problems are not progressive, and indeed in humans, breathing problems may actually be more severe at younger ages (92) . Together, these findings suggest that our understanding of respiratory dysfunction associated with RTT is far from complete, and underscore the need for further examination of animal models of this disease.
Seizures EEG abnormalities and seizures are frequently observed in RTT patients, with seizure prevalence being approximately 60% (93) (94) (95) (96) (97) (98) . In Mecp2 ZFN/y males, we observed seizures as early as the fourth postnatal week, and most strikingly in symptomatic older Mecp2 ZFN/þ females upon behavioural testing or handling.
Previous RTT mouse studies have reported seizures as early as the 5 th -7 th postnatal week in males (11,13,37,99-101) and 4 months of age in females (22) . Although the absence of 24-h video or EEG monitoring made it difficult to define these episodes as seizures and quantify their prevalence, the abnormal behaviour and posture of the rats during these events were clearly reminiscent of seizure activity. The future quantification of seizure activity in this model is warranted, and studies in the rat would be particularly appealing due to the animals' large size and the advantages that this would confer in electrode implantation and EEG recording.
Social aggression
While we did not pursue additional testing measures of social interaction in this model, we did observe many instances of Mecp2 ZFN/y -initiated aggression that resulted in the severe wounding of littermates. These findings may be related to previous reports of altered aggressive or defensive behaviours (17, 18, 99, 102) and anxiety-like behaviours (19, 20, 22, 37, 38, 44, 50, 61) in RTT mouse models as well as in patients (reviewed in (53) ). This aggressive behaviour was not observed in Mecp2 ZFN/þ females.
Musculoskeletal features
Abnormal curvature of the spine, while prevalent in RTT patients (103) and reported in previous mouse models (14) , was not observed in any rats in our study. Throughout development, however, Mecp2 ZFN/y and symptomatic Mecp2 ZFN/þ rats were generally much more easily handled and examined than their WT counterparts due to the display of significant hypotonia. This observation has not previously been described in mouse models of RTT (25) , although early hypotonia is well described in human patients with MECP2 mutations (65, 67, 104) , and several mouse studies have reported alterations in muscular strength in males and females (14, 22, 37, 38, 70) . A recent study utilizing a conditional MeCP2 knockout model has demonstrated that loss of MeCP2 affects skeletal muscle through a non-cell autonomous mechanism leading to disorganized hypotrophic fibres and fibrosis (105) . Preliminary results not presented herein suggest that muscular strength, as assessed by the wire hang and grip strength tests, may be reduced in both juvenile Mecp2 ZFN/y males and 12 month Mecp2 ZFN/þ females; however, genotypespecific body weight differences made these results difficult to meaningfully interpret given that the testing paradigms and data analysis rely heavily on body weight. It is clear that muscle tone is significantly altered, whether mediated through a central or peripheral mechanism, in this rat model. The current model offers a clear advantage in that the sheer size of the laboratory rat makes such features easily detectable.
Concluding Remarks
The characteristics observed in Mecp2 ZFN/y and Mecp2 ZFN/þ rats demonstrate many parallels to those displayed by various mouse models as well as in patients with RTT. It is worth noting that the authors of this publication have additional experience working with the Jaenisch null mouse model of RTT (11), and many of the symptoms described herein are more readily apparent and pronounced in the rat than in the smaller laboratory mouse, especially at very early developmental stages. We believe that this study opens the door to a new avenue of research in the RTT field, as it not only characterizes an entirely new species model of this genetic condition, but does so in both male and female MeCP2-deficient rats throughout development. This novel rat model may serve as a critical tool in improving our understanding of disease progression and subsequently aiding in the development of stage-specific therapeutics.
Materials and Methods
Subjects
All experimental protocols were in accordance with the NIH guidelines and were carried out with approval from the Animal Care and Use Committee of the University of Alabama at Birmingham (Animal Permit Number: 09409). Every effort was made to minimize pain and discomfort. Animals used in all experiments were littermates bred in our animal facility by crosses of Mecp2 ZFN/þ females (SD-Mecp2 tm1sage ) to wildtype (WT) S100b eGFP (enhanced green fluorescent protein) males obtained from the National Bioresource Project Rat (Japan) (106) . This breeding regimen was maintained due to our inherent interest in the study of the role of astrocytes in the pathophysiology of RTT. All rats were genotyped by PCR using DNA obtained from tail snips and Clontech's Terra PCR Direct Genotyping kit. Primers used were the following: forward 5-GCAGCATCA GAAGGTGTTCA-3 and reverse 5-GACCTCAATGCTGACGGTTT-3. Expected bands were the following: WT ¼ 345bp, Mecp2 ZFN/y ¼ 274bp, and Mecp2 ZFN/þ ¼ 345 bp and 274bp (see Fig. 1A ).
Subjects were sacrificed during the study if they displayed active malocclusion, deteriorating body condition, or if they were required for brain weight evaluation. Time between behavioural evaluations in repeatedly tested animals was always at least two weeks. Studies in male rats were not pursued after active malocclusion presented. Animals were housed under standard conditions of 12-h light-dark cycles and were provided with water and food available ad libitum.
Western blotting
Brain regions were dissected from whole tissue and sonicated in lysis buffer containing 1M Tris pH 7.5, 10% SDS, and 1:10 protease and phosphatase inhibitors. Equal amounts of protein (10mg and 7mg of protein from male and female animals, respectively) were electrophoresed on 4-20% Mini-PROTEAN TGX precast polyacrylamide gel (BioRad) for 1.5 h at 200V at room temperature and transferred onto methanol-activated PVDF membranes (Millipore) at 100V for 1 h stirring with a cold pack. Membranes were blocked in 10% nonfat milk prepared in TBS-T shaking for 1 h at room temperature, incubated shaking with mouse monoclonal antibodies against the C-terminus of MeCP2 at 1mg/mL (Sigma) in blocking buffer for 2 h at room temperature (female rat cortex) or 4 h at room temperature (male rat cortex and brainstem), washed 3Â5 min in TBS-T, and incubated shaking with anti-mouse HRP-conjugated IgG 1:2000 (Santa Cruz Biotechnology, lot #E3113) for 1 h at room temperature. Following 3Â5 min washing with TBS-T, blots were developed using Millipore Luminata Classico Western HRP substrate. Clear MeCP2 bands were observed at the expected molecular weight of 75 kD; however, non-specific bands were observed at $200, 50 and 40KD, and were present in WT, Mecp2 ZFN/y and Mecp2 
Brain and body growth curves
Animals were weighed on a weekly basis to the 1/10 th gram to evaluate overall growth and monitor for any weight loss that might necessitate sacrifice. For ages at which brain weights were evaluated, animals were anaesthetized with CO 2 and decapitated. Brains were removed from the skull and weighed to the nearest 1/10 th gram. For body weight evaluation in males, only those rats that did not go on to develop malocclusion by PND 50 were included in analysis, as decelerated weight gain seemed to precede severe tooth lengthening, and active malocclusion led to weight loss. Brain and body weights for each time point evaluated were averaged based on genotype.
Generation of symptom scores
Symptom scores (0-9) were generated on a weekly basis during an observation time of approximately 3-6 min per cage based on the summation of the scores from eight characteristics, with a total score of 9 representing a maximally symptomatic animal. General activity level was scored from 0 to 2, with normal activity (0) including cage exploration, interaction with cagemates, and rearing on the hindquarters during experimenter removal of cage lid, and abnormal activity ranging from lethargic cage exploration and no hindlimb rearing (1) to extreme lethargy or a complete lack of movement during the observation period (2) . The presence of hindlimb clasping, breathing abnormalities (gasping, "hiccuping" or breath holding), waddling or low-clearance gait, unkempt fur, fur loss, urine staining around the genitals, and porphyrin around the eyes or nose all individually yielded a score of 1. Symptom scores were averaged based on genotype and reported for each age.
Open field test
One session consisted of placing each rat in the centre of an open field arena (70 Â 70cm) surrounded by clear plastic walls and recording for a 4-min period. All movement was captured using a camera mounted above the arena and was quantified by Ethovision XT version 11 software (Noldus). Single-session genotypic values were averaged at each time point reported.
Rotor rod test
During one testing session, rats were placed on an accelerating rod of a 5.75" diameter (San Diego Instruments) for three training trials with 2 min rest between each, followed by three recorded test trials with 2 min rest between each. Each trial lasted for a maximum of 10 min, with the rod accelerating linearly from 0 to 5 rpm for the first 30 s, 5 to 10 rpm, 10 to 15 rpm, and 15 to 20 rpm for the remaining three 1.5 min segments, and staying at 20 rpm for a maximum of 5 min if any animal remained on the rod. The amount of time for each rat to fall from the rotating rod onto a foam pad 48" below was recorded for each test trial. Latency to fall values from the three test trials were averaged for each animal and within-genotype session averages were calculated at each age reported.
Catwalk test
All rats were trained with 3 trials on the Catwalk device (Noldus) one week prior to their first testing session. In short, rats were placed at one end of a glass plate of width 10 cm (adults) or 6 cm (pups) enclosed by two opaque walls and a ceiling, and moved toward the other end, which provided an enclosed dark box as a motivating factor for advancement along the surface. During the testing session, trials were video recorded by a camera placed 48.5 cm below the plexiglass surface, thereby capturing the ventral surface of the animals and allowing for measurement of paw placement. For each animal, the first three trials meeting a requirement of <100% within-trial speed variation were kept for analysis. Noldus Catwalk XT version 10.5 software was used to evaluate all gait parameters reported in this study. The Noldus formula used to calculate the regularity index for each trial is as follows: [(NSSP Â 4)/PP] Â 100%, where NSSP represents the number of normal step sequence patterns and PP the total number of paw placements within the trial. The support type values reported reflect the percentage of time in each trial during which the animal had three paws simultaneously placed on the plexiglass plate. For each animal, the value of each reported parameter was determined as an average of the three recorded session test trials, and these values were averaged based on genotype at each age shown.
Whole-body unrestrained plethysmography
Respiratory activity was measured using a constant flow wholebody plethysmograph system (Buxco), utilizing animal chambers (PLY3211 and PLY3213) maintained at room temperature and ventilated with air (1000 mL/min). Respiratory-induced changes in chamber pressure were detected using a pressure transducer calibrated before each experiment by the injection of 1mL or 5mL of air (for PLY3211 and PLY3213, respectively) through a Luer-lock syringe according to Buxco manual guidelines. During a testing session (one per animal per age reported), animals were individually placed into a chamber and allowed 30 min to acclimate prior to data recording. Respiratory activity was then recorded for a period of 25 min, and all experiments were performed between 11am and 6pm to minimize potential circadian effects. Tidal volume (TV) (measured in mL, normalized to body weight and corrected to account for chamber and animal temperature, humidity, and atmospheric pressure), minute ventilation (MV) (mL/min/kg), inspiratory time (Ti) and expiratory time (Te) were recorded continuously using the BioSystem XA for Windows software with a logging rate of 5 s. A 1-min period of relative quiescence was selected from continuous data traces for off-line analysis of all respiratory parameters except apneas. Respiratory frequency (breaths per minute; BPM) was analyzed separately using template search event detection in Axon Clampfit 10.2 (Molecular Devices). We confirmed that the 1-min section of data selected for analysis was devoid of any behaviour artefacts, representative of eupneic breathing over the 25 min period, and appeared stable (i.e., limited interbreath variability) as determined by plotting each breath (n þ 1) against the previous breath (n) and constructing a Poincare plot to confirm close clustering of data points in a manner similar to (107) .
To estimate respiratory cycle variability we calculated the irregularity score (IS) as previously described (108) IS¼ 100 Â ABS(P n -P nÀ1 )/P nÀ1 , where IS is the irregularity score for the nth cycle, P n is its period, P nÀ1 is the period of the preceding cycle, and ABS is the absolute value. The frequency and duration of apneic events were determined for the entire 25-min recording. Apneic events were conservatively defined as periods with a Te ! 3 breath cycles for a juvenile WT (1.4 s) or 3 breathe cycles for an adult male WT (1.6 s).
Statistics
Data are reported as mean 6 standard error of the mean. Statistical analysis was performed using GraphPad InStat 3 software. All parameters in this study were analyzed via within-genotype values at each developmental time point. Between-genotype comparisons were made independently at each age via non-parametric (Mann-Whitney) tests.
Farmer, UAB senior clinical lab veterinarian, provided valuable expertise in the general monitoring of rat health in this study. SageV R Labs provided the supplier name for the antibody that was used in the detection of MeCP2. 
